• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.

作者信息

Ludmir Ethan B, McCaw Zachary R, Wei Lee-Jen

机构信息

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Google LLC, Mountain View, CA, USA.

出版信息

Eur Urol. 2021 Jan;79(1):e10-e11. doi: 10.1016/j.eururo.2020.09.049. Epub 2020 Oct 24.

DOI:10.1016/j.eururo.2020.09.049
PMID:33109378
Abstract
摘要

相似文献

1
Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.回复：卡里姆·菲扎齐、查尔斯·G·德雷克、托马什·M·比尔等人。多西他赛后转移性去势抵抗性前列腺癌放疗后伊匹木单抗与安慰剂对比的III期试验最终分析确定了长期存活者过多。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.07.032：解读伊匹木单抗对多西他赛后转移性去势抵抗性前列腺癌患者放疗后的疗效
Eur Urol. 2021 Jan;79(1):e10-e11. doi: 10.1016/j.eururo.2020.09.049. Epub 2020 Oct 24.
2
Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.对伊桑·B·卢德米尔、扎卡里·R·麦考和李-珍·魏致编辑信的回复：关于卡里姆·菲扎齐、查尔斯·G·德雷克、托马什·M·比尔等人的研究。多西他赛后转移性去势抵抗性前列腺癌放疗后伊匹木单抗与安慰剂对比的III期试验最终分析确定了长期存活者过多。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.07.032。解读放疗后伊匹木单抗对多西他赛后转移性去势抵抗性前列腺癌患者的疗效。
Eur Urol. 2021 Jan;79(1):e12-e13. doi: 10.1016/j.eururo.2020.10.012. Epub 2020 Oct 26.
3
Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients.回复：卡里姆·菲扎齐、金·N·奇、约翰·S·德博诺等。长期给转移性去势抵抗性前列腺癌患者服用醋酸阿比特龙时联合低剂量泼尼松的情况下，皮质类固醇相关不良事件的发生率较低。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.02.035：老年患者的皮质类固醇相关不良事件
Eur Urol. 2016 Aug;70(2):e41. doi: 10.1016/j.eururo.2016.05.004. Epub 2016 May 12.
4
Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients.对吉安多梅尼科·罗维耶洛、阿尔贝托·博蒂尼和达尼埃莱·热纳利致编辑的信的回复，信的主题为：卡里姆·菲扎齐、金恩智、约翰·S·德博诺等人。长期给转移性去势抵抗性前列腺癌患者服用低剂量泼尼松龙联合醋酸阿比特龙时，皮质类固醇相关不良事件的发生率较低。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.02.035。老年患者中的皮质类固醇相关不良事件 。
Eur Urol. 2016 Aug;70(2):e42. doi: 10.1016/j.eururo.2016.05.005. Epub 2016 May 18.
5
Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.回复：安德里亚·勒尔、阿里夫·侯赛因、阿卡什·帕奈克等人。转移性去势抵抗性前列腺癌患者接受鲁卡帕尼治疗后BRCA回复突变的出现。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.09.010 。
Eur Urol. 2023 Mar;83(3):e76-e77. doi: 10.1016/j.eururo.2022.12.024. Epub 2023 Jan 3.
6
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.多西他赛后放疗的转移性去势抵抗性前列腺癌中免疫检查点抑制剂依匹单抗与安慰剂的 III 期试验最终分析确定了长期生存者的人数过多。
Eur Urol. 2020 Dec;78(6):822-830. doi: 10.1016/j.eururo.2020.07.032. Epub 2020 Aug 15.
7
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.回复：约翰·S·德博诺、马修·R·史密斯、弗雷德·萨德等。醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者后的后续化疗及治疗模式：COU-AA-302的事后分析。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.06.033
Eur Urol. 2017 Feb;71(2):e55. doi: 10.1016/j.eururo.2016.08.010. Epub 2016 Aug 16.
8
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.回复：约翰·S·德博诺、马修·R·史密斯、弗雷德·萨德等。醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者后的后续化疗及治疗模式：COU-AA-302的事后分析。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.06.033
Eur Urol. 2017 Jan;71(1):e9-e10. doi: 10.1016/j.eururo.2016.10.006. Epub 2016 Oct 13.
9
Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.对罗伯特·J·范·索斯特和罗纳德·德·威特致编辑的信的回复，信的主题为：约翰·S·德博诺、马修·R·史密斯、弗雷德·萨德等人。醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者后的后续化疗及治疗模式：COU - AA - 302的事后分析。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.06.033 。
Eur Urol. 2017 Jan;71(1):e11. doi: 10.1016/j.eururo.2016.10.005. Epub 2016 Oct 14.
10
Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. Eur Urol. 2020:77:494-500. https://doi.org/10.1016/j.eururo.2019.11.021.回复：松原信明、金恩智、穆斯塔法·奥兹古罗卢等。醋酸阿比特龙加泼尼松或安慰剂联合雄激素剥夺治疗转移性去势敏感性前列腺癌中前列腺特异性抗原动力学与总生存期及无放射学进展生存期的相关性：3期LATITUDE研究的事后分析。《欧洲泌尿外科杂志》。2020年；77:494 - 500。https://doi.org/10.1016/j.eururo.2019.11.021
Eur Urol. 2020 Aug;78(2):e89-e90. doi: 10.1016/j.eururo.2020.03.018. Epub 2020 Apr 11.

引用本文的文献

1
Expression of non-homologous end joining factor, Ku80, is negatively correlated with PD-L1 expression in cancer cells after X-ray irradiation.非同源末端连接因子Ku80的表达与X射线照射后癌细胞中PD-L1的表达呈负相关。
Oncol Lett. 2022 Jan;23(1):29. doi: 10.3892/ol.2021.13147. Epub 2021 Nov 23.
2
The role of radiotherapy in the age of immunotherapy.放疗在免疫治疗时代的作用。
Jpn J Clin Oncol. 2021 Apr 1;51(4):513-522. doi: 10.1093/jjco/hyaa268.